MX2018006779A - Terapia ciclica con 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-p iperidin-2,6-diona. - Google Patents

Terapia ciclica con 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-p iperidin-2,6-diona.

Info

Publication number
MX2018006779A
MX2018006779A MX2018006779A MX2018006779A MX2018006779A MX 2018006779 A MX2018006779 A MX 2018006779A MX 2018006779 A MX2018006779 A MX 2018006779A MX 2018006779 A MX2018006779 A MX 2018006779A MX 2018006779 A MX2018006779 A MX 2018006779A
Authority
MX
Mexico
Prior art keywords
quinazolin
dione
piperidine
oxo
amino
Prior art date
Application number
MX2018006779A
Other languages
English (en)
Inventor
Gandhi Anita
Hagner Patrick
POURDEHNAD Michael
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MX2018006779A publication Critical patent/MX2018006779A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente se proporcionan métodos para tratar, prevenir y/o controlar el cáncer, inclusive linfoma, que comprenden la administración a un paciente de 3-(5-amino-2-metil-4-oxo-4H-quinaz olin-3-il)-piperidin-2,6-diona, o un enantiómero o una mezcla de enantiómeros de este, o una sal, solvato, hidrato, cocristal, clatrato o polimorfo de estos farmacéuticamente aceptables en una pauta de terapia cíclica.
MX2018006779A 2015-12-02 2016-12-01 Terapia ciclica con 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-p iperidin-2,6-diona. MX2018006779A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562262263P 2015-12-02 2015-12-02
PCT/US2016/064392 WO2017096024A1 (en) 2015-12-02 2016-12-01 Cycling therapy using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione

Publications (1)

Publication Number Publication Date
MX2018006779A true MX2018006779A (es) 2018-08-01

Family

ID=57614460

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018006779A MX2018006779A (es) 2015-12-02 2016-12-01 Terapia ciclica con 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-p iperidin-2,6-diona.

Country Status (13)

Country Link
US (1) US10159675B2 (es)
EP (1) EP3383398A1 (es)
JP (1) JP2018535992A (es)
KR (1) KR20180088401A (es)
AU (1) AU2016364753A1 (es)
BR (1) BR112018010964A2 (es)
CA (1) CA3006758A1 (es)
CL (1) CL2018001434A1 (es)
EA (1) EA201891289A1 (es)
IL (1) IL259597A (es)
MX (1) MX2018006779A (es)
SG (1) SG11201804367PA (es)
WO (1) WO2017096024A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017028530A2 (pt) 2015-07-02 2018-08-28 Celgene Corp terapia combinada para tratamento de cânceres hematológicos e tumores sólidos
US20180258064A1 (en) * 2017-03-07 2018-09-13 Celgene Corporation Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
MX2021005366A (es) 2018-11-08 2021-09-10 Juno Therapeutics Inc Metodos y combinaciones para el tratamiento y modulacion de celulas t.
WO2024108028A1 (en) * 2022-11-16 2024-05-23 Salarius Pharmaceuticals, Inc. Methods of use of deuterium-enriched compounds

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2418835A1 (en) 2000-10-16 2002-04-25 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
AU2002256371B2 (en) 2001-04-26 2008-01-10 Amgen Mountain View Inc. Combinatorial libraries of monomer domains
GB0205395D0 (en) * 2002-03-07 2002-04-24 Univ Southampton Materials and methods relating to the treatment of lymphoma
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US20060234299A1 (en) 2004-11-16 2006-10-19 Avidia Research Institute Protein scaffolds and uses thereof
RS52349B (en) 2006-09-26 2012-12-31 Celgene Corporation 5-SUBSTITUTED HINAZOLINONE DERIVATIVES AS ANTITUMOR AGENTS
CN103561743A (zh) * 2011-03-11 2014-02-05 细胞基因公司 利用3-(5-氨基-2-甲基-4-氧-4h-喹唑啉-3-基)-哌啶-2,6-二酮治疗癌症的方法
CA2829570C (en) 2011-03-11 2019-05-07 Celgene Corporation Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
EP3904875A1 (en) * 2012-06-29 2021-11-03 Celgene Corporation Methods for determining drug efficacy using ikzf3 (aiolos)
TW201540323A (zh) 2014-01-15 2015-11-01 Celgene Corp ３－（５－胺基－２－甲基－４－側氧基－４ｈ－喹唑啉－３－基）－哌啶－２，６－二酮之調配物
WO2016007854A1 (en) 2014-07-11 2016-01-14 Celgene Corporation Combination therapy for cancer
BR112017028530A2 (pt) 2015-07-02 2018-08-28 Celgene Corp terapia combinada para tratamento de cânceres hematológicos e tumores sólidos
MX2018002487A (es) 2015-08-27 2018-06-15 Celgene Corp Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinalozin-3-il)-pipe ridin-2,6-diona.

Also Published As

Publication number Publication date
KR20180088401A (ko) 2018-08-03
CL2018001434A1 (es) 2018-08-31
SG11201804367PA (en) 2018-06-28
BR112018010964A2 (pt) 2018-12-04
EA201891289A1 (ru) 2018-11-30
JP2018535992A (ja) 2018-12-06
EP3383398A1 (en) 2018-10-10
IL259597A (en) 2018-07-31
AU2016364753A1 (en) 2018-06-14
US20170157123A1 (en) 2017-06-08
CA3006758A1 (en) 2017-06-08
US10159675B2 (en) 2018-12-25
WO2017096024A1 (en) 2017-06-08

Similar Documents

Publication Publication Date Title
NZ628078A (en) Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
NI201300082A (es) Métodos de tratamiento del cáncer utilizando 3 - ( 5 - amino - 2 - metil - 4 - oxo - 4h - quinazolin - 3 - il ) - piperidin - 2, 6 - diona.
MX2017010477A (es) Compuestos triciclicos y usos de los mismos en medicina.
PH12016502354A1 (en) Pharmaceutical composition
PH12017502142A1 (en) Tetrasubstituted aklene compounds and their use
MX2017000366A (es) Terapia de combinacion para el cancer.
NZ629456A (en) Methods for treating cancer using tor kinase inhibitor combination therapy
PH12014502048B1 (en) Treatment of cancer with tor kinase inhibitors
MX2018006779A (es) Terapia ciclica con 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-p iperidin-2,6-diona.
PH12014502046B1 (en) Treatment of cancer with tor kinase inhibitors
MX2021003842A (es) Terapia combinada para el tratamiento del cancer.
SA515370011B1 (ar) طرق لعلاج سرطان باستخدام علاج توليفي من مركب داي هيدرو بيرازينو-بيرازين
MX2015012650A (es) Metodos para el tratamiento de angioedema mediado receptores debradicinina b2.
MY196979A (en) Method of treating disease by auricular anesthesia of cranial nerves
EA033423B1 (ru) Циклопропанбензофуранилпиридопиразиндионы
MA39599A (fr) Dosage et administration d'agents thérapeutiques anti-egfr
MX2018002487A (es) Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinalozin-3-il)-pipe ridin-2,6-diona.
EA202190865A1 (ru) Комбинированная терапия для лечения рака
MX2015015290A (es) Compuestos furanona como inhibidores de quinasa.
PH12016502107A1 (en) Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
IL283422A (en) Methods of treating or preventing asthma by adding an IL-4R antagonist
IN2014DE00822A (es)
MX2016014011A (es) Farmaco para el tratamiento de pacientes con tinnitus.
EA201491695A1 (ru) Лечение рака ингибиторами tor-киназы